12:00 AM
 | 
Oct 01, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vatreptacog alfa: Development discontinued

Novo Nordisk discontinued development of vatreptacog alfa after data from the double-blind, international Phase IIIa adept 2 trial in 72 patients with congenital hemophilia and inhibitors showed that "a few" patients developed antibodies to the product, including 1 patient who developed antibodies...

Read the full 188 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >